Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Normal
Here is the page describing TT401 from Transition Therapeutics. It's being marketed as a treatment for Type 2 Diabetes.The fastest growing segment of the diabetes market is the class of GLP-1 single-agonist therapies. TT401, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity, is a dual agonist of the GLP-1 (Glucagon-Like Peptide-1) and glucagon receptors. These receptors play an integral role in regulating appetite, food intake, satiety and energy utilization in the body. Stimulating both these receptors, TT401 has the potential to regulate blood glucose levels with important additional outcomes, such as weight loss.Doesn't sound like it binds to androgen receptors, so don't see how it's a SARM.http://www.transitiontherapeutics.com/technology/tt401.php
Here is the page describing TT401 from Transition Therapeutics. It's being marketed as a treatment for Type 2 Diabetes.
The fastest growing segment of the diabetes market is the class of GLP-1 single-agonist therapies. TT401, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity, is a dual agonist of the GLP-1 (Glucagon-Like Peptide-1) and glucagon receptors. These receptors play an integral role in regulating appetite, food intake, satiety and energy utilization in the body. Stimulating both these receptors, TT401 has the potential to regulate blood glucose levels with important additional outcomes, such as weight loss.
Doesn't sound like it binds to androgen receptors, so don't see how it's a SARM.
http://www.transitiontherapeutics.com/technology/tt401.php
We use essential cookies to make this site work, and optional cookies to enhance your experience.
See further information and configure your preferences
